Join Free For Buyer|Sign In
Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn
You are here:  Home >>  

News

Editors' Picks
  • Review progress of the first batch of clinically imperative overseas new drugs
    Developments of Clinically Imperative New Drugs recently.
  • Hot Battle! Which to be the Next “Hanlikang”?
    Hanlikang has been approved for marketing! And its presence has formally started the era of biosimilars in China!

Top Stories

TherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.

TherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.

TherapeuticsMD announced the commercial availability of BIJUVATM (estradiol and progesterone capsules, 1 mg/100 mg) in the United States.
By:americanpharmaceuticalreview
2019.04.18

Research & Development

Mundipharma gets global rights to market digestive health supplement
Mundipharma gets global rights to market digestive health supplement
Zyactinase™ is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for l...
By:biospectrumasia
2018.09.07

Policy & Regulation

FDA approves Merck's Keytruda in combination with Inlyta
FDA approves Merck's Keytruda in combination with Inlyta
Merck has announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy……
By:biospectrumasia
2019.04.23

Company News

Merck’s Keytruda gets FDA approval to treat kidney cancer
Merck’s Keytruda gets FDA approval to treat kidney cancer
Merck has received US Food and Drug Administration (FDA) approval for its anti-PD-1 therapy Keytruda to treat advanced renal cell carcinoma (RCC) p...
By:pharmaceutical-technology
2019.04.24
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat